KalVista Pharmaceuticals, Inc. (KALV) Cantor Global Healthcare Conference 2025 Transcript

Pete Stavropoulos
Biotech Analyst

Welcome to the Cantor Global Healthcare Conference. I’m Pete Stavropoulos, a biotech analyst with Cantor. And with us, we have KalVista, a company we cover. I’m pleased to introduce Ben Palleiko, the CEO of the company. So welcome, Ben. And let’s just start off with a brief intro of yourself and description of KalVista for those who are not familiar.

Benjamin Palleiko
CEO & Director

Thank you for inviting us today. I appreciate all the support from Cantor over the years, and thank you, as usual, for inviting us to this conference. KalVista Pharmaceuticals is a newly commercial stage pharmaceuticals company. This is the first time I get to say this in an investor conference actually. Our drug for treatment of acute attacks of hereditary angioedema, which is called EKTERLY, was approved back in early July by the FDA and was launched immediately afterwards. And actually, we closed our first fiscal quarter as a commercial company on July 31.

In addition to that, we have been pursuing global approvals for EKTERLY. And also in July, we got approval in the U.K. MHRA approved the drug for treatment of attacks as well, and they’ll be launching next year in the U.K. And also at the end of July, the CHMP in the EU recommended approval. That formal approval will come in October. And we’re currently pursuing approvals in 4 other countries as well. So we are on the cusp of being a global commercial pharmaceutical company. But again, with the initial emphasis and right now with a very active launch effort ongoing in the U.S.